News

Cupron Performance Additives (“Cupron”) announces new distribution relationship with Palmer Holland

Cupron Performance Additives (Cupron) announced today the launch of an exclusive distribution agreement with Palmer Holland, leading North American distributor of specialty additives for the engineered materials marketplace. Palmer Holland will distribute Cupron’s copper-based antimicrobial and anti-odor technologies into plastics, films, foams, and polymeric systems throughout North America. The Cupron line effectively complements Palmer Holland’s already best-in-class portfolio of specialty additives for plastics.

The Cupron/Palmer Holland partnership offers customers immediate value backed by cutting-edge science and renowned service. Palmer Holland’s deep knowledge of plastic, film, and foam applications will combine synergistically with Cupron’s most time-tested, well-proven antimicrobial and anti-odor technologies. Cupron products are available now for purchase and sampling from Palmer Holland.

Commenting on the partnership, Chris Andrews, Cupron’s Chief Executive Officer, said,

“We were drawn to Palmer Holland’s reputation for its longstanding differentiated market service. Extensive due diligence only validated our assumptions. Where it matters most, our companies overlap in culture and market objectives. Our thanks to Palmer Holland’s talented sales professionals for their vision and enthusiasm during scale-up discussions. We send gratitude and congratulations to Palmer Holland leaders Vince Misiti, Tony Denton, and Jim Norris for their stewardship of a truly great organization.”

Jim Norris, Market Manager for Engineered Materials at Palmer Holland, commented,

“Palmer Holland’s Engineered Materials Business continues to set itself apart with a distribution model designed to deliver unmatched value to suppliers and customers alike. Our new partnership with Cupron is a perfect fit with our strategy of championing specialty additives and modifiers that redefine performance standards. Cupron brings to the plastic-adjacent market a one-of-a-kind technology that combines proven antimicrobial, biocidal, and antifungal protection with a strong sustainability profile—addressing critical needs in product safety, durability, and environmental responsibility.

Through this collaboration, Palmer Holland will connect Cupron’s innovation with leading compounders and masterbatch producers, enabling the creation of next-generation materials that perform better, last longer, and contribute to a healthier planet.”

 

Read more here.

Recent News

07/20/2026

U.S. Department of Commerce Intends to Invest $169 Million in Tech Hubs Funding to Enhance Economic Competitiveness and National Security

Today, the U.S. Department of Commerce announced that the Economic Development Administration (EDA) intends to award $169 million across six selected Tech Hubs to advance U.S. leadership in industries essential to our economic competitiveness and national security. These projects are part of EDA’s Regional Technology and Innovation Hubs (Tech Hubs) program, which serves as a key investment in this Administration’s America First agenda, investing in regions

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE